Merck & Co. Inc. (MRK)

79.24
0.57 0.71
NYSE : Health Technology
Prev Close 79.81
Open 79.79
Day Low/High 79.08 / 80.12
52 Wk Low/High 52.83 / 80.19
Volume 9.15M
Avg Volume 12.48M
Exchange NYSE
Shares Outstanding 2.60B
Market Cap 207.54B
P/E Ratio 63.85
Div & Yield 2.20 (2.52%)
Merck Announces Appointment Of Jennifer Zachary As General Counsel

Merck Announces Appointment Of Jennifer Zachary As General Counsel

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced the appointment of Jennifer Zachary as general counsel, effective April 16, 2018.

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Square Is One of 4 Upset Picks in Our Latest 'Sweet 16' Stock Selections

Watch for these upstart names to topple some big-caps going forward.

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Merck, Phillips 66, Five Below, Cintas: 'Mad Money' Lightning Round

Jim Cramer focuses on Merck, Eli Lilly, Abbott Labs, Phillips 66, Five Below, and Cintas in the Lightning Round.

Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)

Capitol to Capital: Cramer's 'Mad Money' Recap (Wednesday 3/14/18)

Do we trade on the news out of Washington? Jim Cramer talks about Larry Kudlow and his stand on economic growth.

First-Line Lung Cancer Data And Other New Research From Merck's Broad Oncology Program To Be Presented At AACR Annual Meeting

First-Line Lung Cancer Data And Other New Research From Merck's Broad Oncology Program To Be Presented At AACR Annual Meeting

Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced that new research from Merck's broad oncology clinical program - across several major tumor types, as monotherapy and in combination -...

FDA Grants Priority Review To Merck's Supplemental Biologics License Application (sBLA) For KEYTRUDA® (pembrolizumab) For Treatment Of Advanced Cervical Cancer

FDA Grants Priority Review To Merck's Supplemental Biologics License Application (sBLA) For KEYTRUDA® (pembrolizumab) For Treatment Of Advanced Cervical Cancer

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the U.

Buyers of Merck's Stock Have Become More Bullish in the Past 4 Months

Buyers of Merck's Stock Have Become More Bullish in the Past 4 Months

Let's review the charts and indicators to see where this move may carry in the weeks ahead.

Http://www.merck.com

Http://www.merck.com

Eisai Co., Ltd.

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Asks Drug Companies What They'll Do With Extra Cash From Big Tax Cut

Senator Tina Smith wants some answers from a group of Big Pharma companies about how the new cash flowing from the corporate tax break will be spent.

Merck To Present New Data From Studies Of Investigational HIV Therapies Doravirine And MK-8591 At CROI 2018

Merck To Present New Data From Studies Of Investigational HIV Therapies Doravirine And MK-8591 At CROI 2018

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that data from studies of Merck's robust HIV pipeline, including doravirine, a late-stage investigational non-nucleoside reverse...

Merck Becomes #22 Most Shorted Dow Stock, Replacing UnitedHealth Group

Merck Becomes #22 Most Shorted Dow Stock, Replacing UnitedHealth Group

The most recent short interest data has been released for the 02/15/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer

LYNPARZA® (olaparib) Receives Positive EU CHMP Opinion In Platinum-Sensitive Relapsed Ovarian Cancer

AstraZeneca and Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency has adopted a positive...

Http://www.merck.com

Http://www.merck.com

Merck (NYSE: MRK), known as MSD outside the United States and Canada, and Viralytics Limited (ASX: VLA, OTC: VRACY) today announced that the companies have signed a definitive agreement under which it is proposed that...

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

The Jury Is Still Out on Merck

The Jury Is Still Out on Merck

When the broad market rallies and your stock does not participate there is a message there and that bothers me.

Selumetinib Granted Orphan Drug Designation By The U.S. FDA For Neurofibromatosis Type 1

Selumetinib Granted Orphan Drug Designation By The U.S. FDA For Neurofibromatosis Type 1

AstraZeneca and Merck (NYSE:MRK), known as MSD outside the U.S.

Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat (MK-8931) For The Treatment Of People With Prodromal Alzheimer's Disease

Merck Announces Discontinuation Of APECS Study Evaluating Verubecestat (MK-8931) For The Treatment Of People With Prodromal Alzheimer's Disease

Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced that it will be stopping protocol 019, also known as the APECS study, a Phase 3 study evaluating verubecestat (MK-8931), an...

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Volatility Is Still in Charge: Cramer's 'Mad Money' Recap (Friday, 2/9/18)

Jim Cramer tackles the volatility issue and outlines the game plan for next week.

Taking Merck's Temperature

Taking Merck's Temperature

How far MRK can travel in the next few weeks is key.

Jim Cramer: These 4 Stocks Seem Attractive Right Here

Jim Cramer: These 4 Stocks Seem Attractive Right Here

There is nothing wrong with Intel, Johnson & Johnson, 3M and Apple.

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

Why Investors Shouldn't Worry About Trump's Tough Talk on Drug Prices

While Donald Trump's tweets can shake up pharmaceutical stocks, history suggests that investors have little to fear from the president's drug pricing rhetoric.

Merck Becomes #20 Most Shorted Dow Stock, Replacing Walt Disney C

Merck Becomes #20 Most Shorted Dow Stock, Replacing Walt Disney C

The most recent short interest data has been released for the 01/12/2018 settlement date, and we here at Dividend Channel like to sift through this fresh data and order the underlying components of the Dow Jones Industrial Average by "days to cover." There are a number of ways to look at short data, for example the total number of shares short; but one metric that we find particularly useful is the "days to cover" metric because it considers both the total shares short and the average daily volume of shares typically traded. The number of shares short is then compared to the average daily volume, in order to calculate the total number of trading days it would take to close out all of the open short positions if every share traded represented a short position being closed.

First-of-its-Kind Study Reveals Concern About The Future Of The Veterinary Profession

First-of-its-Kind Study Reveals Concern About The Future Of The Veterinary Profession

Merck Animal Health (known as MSD Animal Health outside the United States and Canada) today announced the results of a large, well-controlled study with veterinarians designed to definitively quantify the prevalence of...

Centene, LabCorp Among Healthcare Stock Gainers

Centene, LabCorp Among Healthcare Stock Gainers

Centene and Laboratory Corp. of America were among the healthcare stocks in the green on Tuesday, Feb. 6, amid a volatile trading day in the stock market.

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

Pharma Execs Talk M&A, Drug Pricing Pressures on Earnings Calls

'I think everybody is looking at potential combinations and consolidations,' Pfizer CEO Ian Read said on an earnings call on Tuesday, Jan. 30.

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

It's Bad, but It's Not a Crash: Cramer's 'Mad Money' Recap (Friday 2/2/18)

In a special edition of Mad money, Jim Cramer examines this brutal decline and lays out the game plan for next week -- live from Minneapolis ahead of the Super Bowl.

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Shopify, Kinder Morgan, Pfizer: 'Mad Money' Lightning Round

Jim Cramer highlights Shopify, Kinder Morgan, Thermo Fisher Scientific, Radius Health, Merck, Pfizer and more.

Dow Gets Walloped, Falls 665 Points as Bond Yields Spike

Dow Gets Walloped, Falls 665 Points as Bond Yields Spike

Stocks plunge and Treasury yields spike after the U.S. adds 200,000 jobs to payrolls in January and wages increase.

Stocks Slide and Amazon's Profit Soars - 5 Things You Must Know

Stocks Slide and Amazon's Profit Soars - 5 Things You Must Know

U.S. stock futures are falling sharply on Friday as bond yields jump, Apple posts a mixed quarter, and Wall Street awaits the U.S. jobs report for January.

Unfortunately Red Hot Economic Data Supports Higher Interest Rates

Unfortunately Red Hot Economic Data Supports Higher Interest Rates

Economic conditions seem to be improving for laborers. Perhaps rapidly.

TheStreet Quant Rating: A+ (Buy)